CompanyDrug

MSD and Daiichi Sankyo’s Patritumab Deruxtecan Achieves Milestone in Phase III Lung Cancer Trial

CompanyDrug

GSK’s Blenrep-BorDex Combo Earns Breakthrough Therapy Designation in China for Multiple Myeloma

CompanyDrug

AstraZeneca’s Imfinzi-Imjudo Combo Sets New Longevity Benchmark in Liver Cancer Treatment

CompanyDrug

BeiGene’s Tislelizumab Receives Israeli Nod for Oesophageal Cancer Treatment

CompanyDrug

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Shows Positive Phase I Results at ESMO Congress

CompanyDrug

Alphamab Oncology’s JSKN003 ADC Achieves Positive Safety and Efficacy Outcomes in Phase I Studies

CompanyDrug

CStone Pharmaceuticals’ Sugemalimab Shows Promising Long-Term Survival Data at ESMO 202

CompanyDrug

Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US

Company

Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements

CompanyDrug

Dizal Pharmaceutical’s Sunvozertinib Shows Promising Results in WU-KONG Series Study at ESMO 2024

Policy / Regulatory

NHSA Concludes 2024 NRDL Review, Announces Submission Deadlines for Drug Manufacturers

CompanyMedical Device

MicroPort Scientific’s Firesorb Bioabsorbable Stent Begins Clinical Use in China